These results support the therapeutic strategies that restore the function of stathmin-2 in ALS and other stathmin-2 and TDP-43-related conditions (https://www.neurologylive.com/view/first-ever-study-of-stathmin-2-therapy-als-commences, accessed on 5 May 2024). This evidence concerns the gene STMN2 and amyotrophic lateral sclerosis.